CNBC: Judge mulls not approving CVS-Aetna agreement

Amy Baxter | | Health Exec | Policy & Regulations

While the $69 billion merger between CVS Health and Aetna has been approved by regulators and cleared by the Department of Justice, a federal judge has raised the prospect of not approving the deal, CNBC reported.

A judge from the U.S. District Court for the District of Columbia noted the deal, which closed Nov. 28, was given a “rubber stamp” treatment by governments, according to CNBC. Despite being approved by other regulators, the agreement between the government and the two companies must also be approved by the court.

According to Aetna, the situation is “commonplace,” CNBC reported.

See the full story below:

US judge raises prospect of not approving CVS-Aetna deal

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

HHS employees offered two months of pay to quit their jobs
To tell or not to tell: Do patients really need to know who—or what—writes their doctor’s notes?
CMS ends ACA special enrollment, changes deadline for signing up
Report: NIH continues to pull research grants, in violation of court orders
HHS sends 80K workers a $25K ‘voluntary’ resignation notice
More than 1,000 hospitals earn $700M opioid crisis judgment

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.